Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238377 | 1.00 | CYP19A1 (0.50) | CYP19A1GRM2CYP3A4CYP2C9 | |
| SCHEMBL7144171 | 1.00 | CYP19A1 (0.50) | CYP19A1GRM2CYP3A4CYP2C9 | |
| SCHEMBL5233140 | 0.83 | CYP3A4 (0.42) | GRM2CYP3A4CYP2C9 | |
| SCHEMBL5239547 | 0.80 | MAOA (0.56) | CYP3A4 | |
| SCHEMBL11594531 | 0.77 | GRM2 (0.50) | GRM2 | |
| SCHEMBL9815504 | 0.77 | GRM2 (0.50) | GRM2 | |
| SCHEMBL10878982 | 0.77 | MAOA (0.56) | GRM2 | |
| SCHEMBL9815496 | 0.77 | GRM2 (0.50) | GRM2 | |
| SCHEMBL9815526 | 0.77 | MAOA (0.56) | GRM2 | |
| SCHEMBL9815487 | 0.77 | GRM2 (0.50) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | CYP19A1 1609/4885GRM2 4159/4885CYP3A4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.